Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00002235
Ignite Creation Date: 2024-05-05 @ 11:08 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00002235
Protocol Section: NCT00002235
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors NNRTIs or Protease Inhibitors
Official Title: A Phase II 48-Week Open-Label Study Designed to Evaluate the Safety Tolerability and Efficacy of a Simplified Dosing Regimen of Viracept Nelfinavir Mesylate 1250 Mg BID Crixivan Indinavir Sulfate 1200mg q12h and Sustiva Efavirenz DMP-266 600 Mg q24h for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Transcriptase Inhibitor and Protease Inhibitor Naive Patients
Acronym: None
Organization: NIH AIDS Clinical Trials Information Service
Organization Class: INDUSTRY
Organization Study ID: 259G
Secondary IDs
Secondary ID Type Domain Link
ICC 602 None None None
Start Status Module Data
Status Verified Date: 2000-03
Overall Status: COMPLETED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Merck Sharp Dohme LLC
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Merck Sharp Dohme LLC
Start Oversight Module Data No Oversight Module Defined
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload